Literature DB >> 18959457

Promotion of initiated cells by radiation-induced cell inactivation.

W F Heidenreich1, H G Paretzke.   

Abstract

Cells on the way to carcinogenesis can have a growth advantage relative to normal cells. It has been hypothesized that a radiation-induced growth advantage of these initiated cells might be induced by an increased cell replacement probability of initiated cells after inactivation of neighboring cells by radiation. Here Monte Carlo simulations extend this hypothesis for larger clones: The effective clonal expansion rate decreases with clone size. This effect is stronger for the two-dimensional than for the three-dimensional situation. The clones are irregular, far from a circular shape. An exposure-rate dependence of the effective clonal expansion rate could come in part from a minimal recovery time of the initiated cells for symmetric cell division.

Mesh:

Year:  2008        PMID: 18959457     DOI: 10.1667/RR0957.1

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  4 in total

1.  Lung cancer mortality in the European uranium miners cohorts analyzed with a biologically based model taking into account radon measurement error.

Authors:  W F Heidenreich; L Tomasek; B Grosche; K Leuraud; D Laurier
Journal:  Radiat Environ Biophys       Date:  2012-05-24       Impact factor: 1.925

2.  Mutation induction by inhaled radon progeny modeled at the tissue level.

Authors:  Balázs G Madas; Imre Balásházy
Journal:  Radiat Environ Biophys       Date:  2011-09-06       Impact factor: 1.925

3.  Beyond two-stage models for lung carcinogenesis in the Mayak workers: implications for plutonium risk.

Authors:  Sascha Zöllner; Mikhail E Sokolnikov; Markus Eidemüller
Journal:  PLoS One       Date:  2015-05-22       Impact factor: 3.240

4.  Genomic instability and radiation risk in molecular pathways to colon cancer.

Authors:  Jan Christian Kaiser; Reinhard Meckbach; Peter Jacob
Journal:  PLoS One       Date:  2014-10-30       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.